CTLA4 and non-small cell lung carcinoma: Recently, chemoimmunotherapy (comprising anti‐programmed death 1 [PD‐1]/programmed death ligand 1 [PD‐L1] antibody plus cytotoxic anticancer agents, and anti‐cytotoxic‐T‐lymphocyte‐associated protein 4 [CTLA‐4] antibody plus anti‐PD‐1/PD‐L1 antibody plus cytotoxic anticancer agents) has emerged as a first‐line treatment for advanced NSCLC, demonstrating efficacy in multiple phase III trials.1, 2, 3, 4, 5, 6, 7